Memantine (MEM) acts on the glutamatergic system by blocking N-methyl-d-aspartate (NMDA) glutamate receptors. The role that MEM plays in protecting retinal cells is unknown. Hydroquinone (HQ) is one of the cytotoxic components in cigarette smoke. In the present study, we tested whether pretreatment with MEM could protect against the cytotoxic effects of HQ on human retinal pigment epithelium cells (ARPE-19) and human retinal Müller cells (MIO-M1) in vitro.
Methods:
Cells were plated, pretreated for 6 h with 30 μM of MEM, and then exposed for 24 h to 200, 100, 50, and 25 μM of HQ while MEM was still present. Cell viability (CV), reactive oxygen species (ROS), mitochondrial membrane potential (ΔΨm), and lactate dehydrogenase (LDH) release assays were performed.
Results:
HQ-treated cells showed a dose-dependent decrease in CV and ΔΨm, but an increase in ROS production and LDH levels in both cell lines. MEM pretreatment reversed the CV in 50, 100, and 200 μM doses in ARPE-19 cells and at all HQ concentrations in MIO-M1 cells compared to HQ-treated cultures. ROS production was reversed in all HQ concentrations in both cell lines. ΔΨm was significantly increased after MEM pretreatment only in 50 μM HQ concentration for both cell lines. LDH levels were decreased at 50 and 25 μM HQ in ARPE-19 and MIO-M1 cells, respectively.
Conclusion:
HQ-induced toxicity is concentration dependent in ARPE-19 and MIO-M1 cultures. MEM exerts protective effects against HQ-induced toxicity on human retinal pigment epithelial and Müller cells in vitro.
Get full access to this article
View all access options for this article.
References
1.
FanX., SunD., TangX., CaiY., YinZ.Q., and XuH.Stem-cell challenges in the treatment of Alzheimer's disease: a long way from bench to bedside. Med. Res. Rev., 34:957–978, 2014.
2.
BayerA.U., FerrariF., and ErbC.High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur. Neurol., 47:165–168, 2002.
3.
GuoL., DugganJ., and CordeiroM.F.Alzheimer's disease and retinal neurodegeneration. Curr. Alzheimer Res., 7:3–14, 2010.
4.
BlanksJ.C., TorigoeY., HintonD.R., and BlanksR.H.Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging., 17:377–384, 1996.
5.
KeslerA., VakhapovaV., KorczynA.D., NaftalievE., and NeudorferM.Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin. Neurol. Neurosurg., 113:523–526, 2011.
6.
DonosoL.A., KimD., FrostA., CallahanA., and HagemanG.The role of inflammation in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol., 51:137–152, 2006.
7.
CurcioC.A., JohnsonM., HuangJ.D., and RudolfM.Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog. Retin. Eye Res., 28:393–422, 2009.
8.
DutescuR.M., LiQ.X., CrowstonJ., MastersC.L., BairdP.N., and CulvenorJ.G.Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Graefes Arch. Clin. Exp. Ophthalmol., 247:1213–1221, 2009.
9.
NingA., CuiJ., ToE., AsheK.H., and MatsubaraJ.Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest. Ophthalmol. Vis. Sci., 49:5136–5143, 2008.
10.
PerezS.E., LumayagS., KovacsB., MufsonE.J., and XuS.Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest. Ophthalmol. Vis. Sci., 50:793–800, 2009.
11.
GerzonK., KrumkalnsE.V., BrindleR.L., MarshallF.J., and RootM.A.The adamantyl group in medicinal agents. I. Hypoglycemic N-Arylsulfonyl-N′ -Adamantylureas. J. Med. Chem., 6:760–763, 1963.
12.
GrossmannW., and SchutzW.[Memantine and neurogenic bladder disorders within the bounds of spastic conditions]. Arzneimittelforschung. 32:1273–1276, 1982.
13.
MiltnerF.O.[Valve of symptomatic therapy with memantine in cerebral coma. II. Development of stretch synergisms in coma with brain stem symptoms]. Arzneimittelforschung., 32:1271–1273, 1982.
14.
SchneiderE., FischerP.A., ClemensR., BalzereitF., FunfgeldE.W., and HaaseH.J.[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]. Dtsch. Med. Wochenschr., 109:987–990, 1984.
15.
MundingerF., and MiliosE.[Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery]. Nervenarzt. 56:106–109, 1985.
16.
BormannJ.Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol., 166:591–592, 1989.
17.
HareW.A., and WheelerL.Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine. Invest. Ophthalmol. Vis. Sci., 50:2940–2948, 2009.
18.
AlleyG.M., BaileyJ.A., ChenD., RayB., PuliL.K., TanilaH., BanerjeeP.K., and LahiriD.K.Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J. Neurosci. Res., 88:143–154, 2010.
19.
SunD., ChenJ., BaoX., CaiY., ZhaoJ., HuangJ., HuangW., FanX., and XuH.Protection of radial glial-like cells in the hippocampus of APP/PS1 mice: a novel mechanism of memantine in the treatment of Alzheimer's disease. Mol. Neurobiol., 52:464–477, 2015.
20.
WuH.M., TzengN.S., QianL., WeiS.J., HuX., ChenS.H., RawlsS.M., FloodP., HongJ.S., and LuR.B.Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology. 34:2344–2357, 2009.
21.
RabeyJ.M., NissipeanuP., and KorczynA.D.Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 4:277–282, 1992.
22.
GauthierS., HerrmannN., FerreriF., and AgbokouC.Use of memantine to treat Alzheimer's disease. CMAJ. 175:501–502, 2006.
23.
KimB.Y., BaeW.Y., HurD.Y., KimJ.R., KohT.K., LeeT.H., and ParkG.B.Effects of memantine on aminoglycoside-induced apoptosis of spiral ganglion cells in guinea pigs. Otolaryngol. Head Neck Surg., 155:147–154, 2016.
24.
LiptonS.A.Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol., 48Suppl 1:S38–S46, 2003.
25.
EsfahaniM.R., HarandiZ.A., MovasatM., NikdelM., AdelpourM., MomeniA., MeratH., and FardM.A.Memantine for axonal loss of optic neuritis. Graefes Arch. Clin. Exp. Ophthalmol., 250:863–869, 2012.
26.
JuW.K., KimK.Y., AngertM., Duong-PolkK.X., LindseyJ.D., EllismanM.H., and WeinrebR.N.Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest. Ophthalmol. Vis. Sci., 50:707–716, 2009.
27.
OsborneN.N.Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis. Neurosci., 16:45–52, 1999.
28.
YigitU., ErdenozS., UsluU., ObaE., CumbulA., CagatayH., AktasS., and EskicogluE.An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury. Mol. Vis., 17:1024–1033, 2011.
29.
Abdel-HamidA.A., Firgany AelD., and AliE.M.Effect of memantine: a NMDA receptor blocker, on ethambutol-induced retinal injury. Ann. Anat., 204:86–92, 2016.
30.
AtorfJ., ScholzM., GarreisF., LehmannJ., BrauerL., and KremersJ.Functional protective effects of long-term memantine treatment in the DBA/2J mouse. Doc. Ophthalmol., 126:221–232, 2013.
31.
VorwerkC.K., LiptonS.A., ZurakowskiD., HymanB.T., SabelB.A., and DreyerE.B.Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest. Ophthalmol. Vis. Sci., 37:1618–1624, 1996.
32.
MansoorS., GuptaN., Luczy-BachmanG., LimbG.A., KuppermannB.D., and KenneyM.C.Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro. Toxicology. 271:107–114, 2010.
33.
MansoorS., GuptaN., PatilA.J., Estrago-FrancoM.F., RamirezC., MigonR., SapkalA., KuppermannB.D., and KenneyM.C.Inhibition of apoptosis in human retinal pigment epithelial cells treated with benzo(e)pyrene, a toxic component of cigarette smoke. Invest. Ophthalmol. Vis. Sci., 51:2601–2607, 2010.
34.
ThorntonJ., EdwardsR., MitchellP., HarrisonR.A., BuchanI., and KellyS.P.Smoking and age-related macular degeneration: a review of association. Eye (Lond). 19:935–944, 2005.
35.
Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology., 107:2224–2232, 2000.
36.
ClemonsT.E., MiltonR.C., KleinR., SeddonJ.M., and FerrisF.L., 3rd; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS): AREDS report no. 19. Ophthalmology., 112:533–539, 2005.
37.
NeunerB., WellmannJ., DaschB., BehrensT., ClaesB., DietzelM., PauleikhoffD., and HenseH.W.Modeling smoking history: a comparison of different approaches in the MARS study on age-related maculopathy. Ann. Epidemiol., 17:615–621, 2007.
38.
ChewE.Y., ClemonsT.E., AgronE., SperdutoR.D., SangiovanniJ.P., DavisM.D., and FerrisF.L., 3rd; Age-Related Eye Disease Study Research Group. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol., 132:272–277, 2014.
39.
CascellaR., RagazzoM., StrafellaC., MissiroliF., BorgianiP., AngelucciF., MarsellaL.T., CusumanoA., NovelliG., RicciF., and GiardinaE.Age-related macular degeneration: insights into inflammatory genes. J. Ophthalmol., 2014:582842, 2014.
40.
ChirasD., KitsosG., PetersenM.B., SkalidakisI., and KroupisC.Oxidative stress in dry age-related macular degeneration and exfoliation syndrome. Crit. Rev. Clin. Lab. Sci., 52:12–27, 2015.
41.
TalhoutR., SchulzT., FlorekE., van BenthemJ., and WesterP., OpperhuizenA.Hazardous compounds in tobacco smoke. Int. J. Environ. Res. Public Health., 8:613–628, 2011.
42.
World Health Organization. WHO Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco product regulations: fifth report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 1–234, 2015, back cover.
43.
PryorW.A.Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ. Health Perspect., 105Suppl 4:875–882, 1997.
44.
BoltonJ.L., TrushM.A., PenningT.M., DryhurstG., and MonksT.J.Role of quinones in toxicology. Chem. Res. Toxicol., 13:135–160, 2000.
45.
DraelosZ.D.Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream. Dermatol. Surg., 31:799–804, 2005.
46.
BechtoldW.E., SunJ.D., BirnbaumL.S., YinS.N., LiG.L., KasickiS., LucierG., and HendersonR.F.S-phenylcysteine formation in hemoglobin as a biological exposure index to benzene. Arch. Toxicol., 66:303–309, 1992.
47.
DeisingerP.J., HillT.S., and EnglishJ.C.Human exposure to naturally occurring hydroquinone. J. Toxicol. Environ. Health., 47:31–46, 1996.
48.
PatilA.J., GramajoA.L., SharmaA., SeigelG.M., KuppermannB.D., and KenneyM.C.Differential effects of nicotine on retinal and vascular cells in vitro. Toxicology. 259:69–76, 2009.
49.
SharmaA., PatilJ.A., GramajoA.L., SeigelG.M., KuppermannB.D., and KenneyCM.Effects of hydroquinone on retinal and vascular cells in vitro. Indian J. Ophthalmol., 60:189–193, 2012.
50.
RamirezC., PhamK., FrancoM.F., ChwaM., LimbA., KuppermannB.D., and KenneyM.C.Hydroquinone induces oxidative and mitochondrial damage to human retinal Müller cells (MIO-M1). Neurotoxicology. 39:102–108, 2013.
51.
National Toxicology Program. NTP toxicology and carcinogenesis studies of hydroquinone (CAS No. 123-31-9) in F344/N rats and B6C3F1 mice (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser., 366:1–248, 1989.
52.
ShibataM.A., HiroseM., TanakaH., AsakawaE., ShiraiT., and ItoN.Induction of renal cell tumors in rats and mice, and enhancement of hepatocellular tumor development in mice after long-term hydroquinone treatment. Jpn. J. Cancer Res., 82:1211–1219, 1991.
53.
Espinosa-HeidmannD.G., SunerI.J., CatanutoP., HernandezE.P., Marin-CastanoM.E., and CousinsS.W.Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest. Ophthalmol. Vis. Sci., 47:729–737, 2006.
54.
AlcazarO., CousinsS.W., and Marin-CastanoM.E.MMP-14 and TIMP-2 overexpression protects against hydroquinone-induced oxidant injury in RPE: implications for extracellular matrix turnover. Invest. Ophthalmol. Vis. Sci., 48:5662–5670, 2007.
55.
PonsM., and Marin-CastanoM.E.Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo. PLoS One. 6:e16722, 2011.
56.
RamirezC., Caceres-Del-CarpioJ., ChuJ., ChuJ., MoustafaM.T., ChwaM., LimbG.A., KuppermannB.D., and KenneyM.C.Brimonidine can prevent in vitro hydroquinone damage on retinal pigment epithelium cells and retinal Müller cells (MIO-M1). J. Ocul. Pharmacol. Ther., 32:102–108, 2016.
DunnK.C., Aotaki-KeenA.E., PutkeyF.R., and HjelmelandL.M.ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res., 62:155–169, 1996.
59.
SarthyP.V., and LamD.M.Biochemical studies of isolated glial (Müller) cells from the turtle retina. J. Cell. Biol., 78:675–684, 1978.
60.
ConstableP.A., and LawrensonJ.G.Glial cell factors and the outer blood retinal barrier. Ophthalmic Physiol. Opt., 29:557–564, 2009.
61.
FranzeK., GroscheJ., SkatchkovS.N., SchinkingerS., FojaC., SchildD., UckermannO., TravisK., ReichenbachA., and GuckJ.Müller cells are living optical fibers in the vertebrate retina. Proc. Natl. Acad. Sci. U. S. A., 104:8287–8292, 2007.
62.
EdwardsR.B., AdlerA.J., DevS., and ClaycombR.C.Synthesis of retinoic acid from retinol by cultured rabbit Müller cells. Exp. Eye Res., 54:481–490, 1992.
63.
LimbG.A., SaltT.E., MunroP.M., MossS.E., and KhawP.T.In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1). Invest. Ophthalmol. Vis. Sci., 43:864–869, 2002.
64.
ChwaM., AtilanoS.R., ReddyV., JordanN., KimD.W., and KenneyM.C.Increased stress-induced generation of reactive oxygen species and apoptosis in human keratoconus fibroblasts. Invest. Ophthalmol. Vis. Sci., 47:1902–1910, 2006.
65.
BurkeJ.M.Epithelial phenotype and the RPE: is the answer blowing in the Wnt?. Prog. Retin. Eye Res., 27:579–595, 2008.
66.
AlizadehM., WadaM., GelfmanC.M., HandaJ.T., HjelmelandL.M.Downregulation of differentiation specific gene expression by oxidative stress in ARPE-19 cells. Invest. Ophthalmol. Vis. Sci., 42:2706–2713, 2001.
67.
GaoY., HuY.Z., LiR.S., HanZ.T., GengY., XiaZ., DuW.J., LiuL.X., ZhangH.H., and WangL.N.Cattle encephalon glycoside and ignotin injection improves cognitive impairment in APPswe/PS1dE9 mice used as multitarget anti-Alzheimer's drug candidates. Neuropsychiatr. Dis. Treat., 11:537–548, 2015.
68.
Jantas-SkotnicznaD., KajtaM., and LasonW.Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures. Brain Res. 1069:145–153, 2006.
69.
TianJ., IshibashiK., HondaS., BoylanS.A., HjelmelandL.M., and HandaJ.T.The expression of native and cultured human retinal pigment epithelial cells grown in different culture conditions. Br. J. Ophthalmol., 89:1510–1517, 2005.
